These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
926 related articles for article (PubMed ID: 33524423)
41. Prevalence of SARS-CoV-2 antibodies after one-year follow up among workers in a research institute in Japan. Nishikimi A; Watanabe K; Watanabe A; Yasuoka M; Watanabe R; Oshima H; Kitagawa Y; Tokuda H; Niida S; Kojima M J Infect; 2022 Jan; 84(1):e23-e25. PubMed ID: 34728267 [No Abstract] [Full Text] [Related]
42. Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare workers with differing levels of coronavirus disease 2019 (COVID-19) patient exposure. Hunter BR; Dbeibo L; Weaver CS; Beeler C; Saysana M; Zimmerman MK; Weaver L Infect Control Hosp Epidemiol; 2020 Dec; 41(12):1441-1442. PubMed ID: 32741406 [TBL] [Abstract][Full Text] [Related]
43. COVID-19 Seroprevalence among Healthcare Workers of a Large COVID-19 Hospital in Rome Reveals Strengths and Limits of Two Different Serological Tests. Vetrugno G; La Milia DI; D'Ambrosio F; Di Pumpo M; Pastorino R; Boccia S; Ricci R; De-Giorgio F; Cicconi M; Foti F; Pascucci D; Castrini F; Carini E; Cambieri A; D'Alfonso ME; Capalbo G; Fantoni M; Moscato U; Staiti D; De Simone FM; Berloco F; Damiani G; Zega M; Cattani P; Posteraro B; Sanguinetti M; Laurenti P Int J Environ Res Public Health; 2021 Mar; 18(5):. PubMed ID: 33800721 [TBL] [Abstract][Full Text] [Related]
44. Altitude and SARS-CoV-2 Infection in the First Pandemic Wave in Spain. Castilla J; Fresán U; Trobajo-Sanmartín C; Guevara M Int J Environ Res Public Health; 2021 Mar; 18(5):. PubMed ID: 33806642 [TBL] [Abstract][Full Text] [Related]
45. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study. Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW; Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432 [TBL] [Abstract][Full Text] [Related]
46. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan. Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990 [TBL] [Abstract][Full Text] [Related]
47. SARS-CoV-2 Seropositivity in Asymptomatic Frontline Health Workers in Ibadan, Nigeria. Olayanju O; Bamidele O; Edem F; Eseile B; Amoo A; Nwaokenye J; Udeh C; Oluwole G; Odok G; Awah N Am J Trop Med Hyg; 2021 Jan; 104(1):91-94. PubMed ID: 33185181 [TBL] [Abstract][Full Text] [Related]
48. Unrecognized severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence among healthcare personnel in a low-prevalence area. Shah VP; Hainy CM; Swift MD; Breeher LE; Theel ES; Sampathkumar P Infect Control Hosp Epidemiol; 2021 Dec; 42(12):1532-1534. PubMed ID: 33213552 [No Abstract] [Full Text] [Related]
49. Low rate of COVID-19 seroconversion in health-care workers at a Department of Infectious Diseases in Sweden during the later phase of the first wave; a prospective longitudinal seroepidemiological study. Rashid-Abdi M; Krifors A; Sälléber A; Eriksson J; Månsson E Infect Dis (Lond); 2021 Mar; 53(3):169-175. PubMed ID: 33232190 [No Abstract] [Full Text] [Related]
50. Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers. Fong D; San Nicolò KO; Alber M; Mitterer M Wien Klin Wochenschr; 2021 Apr; 133(7-8):359-363. PubMed ID: 33502609 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients' Management. Speletas M; Kyritsi MA; Vontas A; Theodoridou A; Chrysanthidis T; Hatzianastasiou S; Petinaki E; Hadjichristodoulou C Front Immunol; 2020; 11():609242. PubMed ID: 33424863 [TBL] [Abstract][Full Text] [Related]
52. Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening. Pagani G; Conti F; Giacomelli A; Bernacchia D; Rondanin R; Prina A; Scolari V; Gandolfi CE; Castaldi S; Marano G; Ottomano C; Boracchi P; Biganzoli E; Galli M J Infect; 2020 Dec; 81(6):e10-e12. PubMed ID: 32961253 [TBL] [Abstract][Full Text] [Related]
53. Testing for COVID-19: a few points to remember. Krátká Z; Luxová Š; Malíčková K; Fürst T; Šimková H Cas Lek Cesk; 2020; 159(2):72-77. PubMed ID: 32434339 [TBL] [Abstract][Full Text] [Related]
54. SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. den Hartog G; Schepp RM; Kuijer M; GeurtsvanKessel C; van Beek J; Rots N; Koopmans MPG; van der Klis FRM; van Binnendijk RS J Infect Dis; 2020 Oct; 222(9):1452-1461. PubMed ID: 32766833 [TBL] [Abstract][Full Text] [Related]
55. Seroprevalence of SARS-CoV-2 Antibodies Among Health Care Personnel at a Health Care System in Pakistan. Abbas S; Raza A; Iftikhar A; Khan A; Khan S; Yusuf MA Asia Pac J Public Health; 2021 Jul; 33(5):632-634. PubMed ID: 33880961 [No Abstract] [Full Text] [Related]
56. Prospective Sero-epidemiological Evaluation of SARS-CoV-2 among Health Care Workers in a German Secondary Care Hospital. Herzberg J; Vollmer T; Fischer B; Becher H; Becker AK; Sahly H; Honarpisheh H; Guraya SY; Strate T; Knabbe C Int J Infect Dis; 2021 Jan; 102():136-143. PubMed ID: 33075538 [TBL] [Abstract][Full Text] [Related]
57. Seroprevalence of anti-SARS-CoV-2 IgG among healthcare workers of a large university hospital in Milan, Lombardy, Italy: a cross-sectional study. Lombardi A; Mangioni D; Consonni D; Cariani L; Bono P; Cantù AP; Tiso B; Carugno M; Muscatello A; Lunghi G; Pesatori AC; Riboldi L; Ceriotti F; Bandera A; Gori A BMJ Open; 2021 Feb; 11(2):e047216. PubMed ID: 33619203 [TBL] [Abstract][Full Text] [Related]
58. High SARS-CoV-2 seroprevalence among health care workers in Bamako referral hospitals: a prospective multisite cross-sectional study (ANRS COV11). Maiga AI; Saliou M; Kodio A; Traore AM; Dabo G; Flandre P; Fofana DB; Ammour K; Tra NOME; Dolo O; Marcelin AG; Todesco E Clin Microbiol Infect; 2022 Jun; 28(6):900-902. PubMed ID: 35182761 [No Abstract] [Full Text] [Related]
59. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310 [TBL] [Abstract][Full Text] [Related]
60. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]